Affiliation:
1. Department of Cancer Biology Dana-Farber Cancer Institute Boston MA 02215 USA
2. Tumor Initiation and Maintenance Program NCI-Designated Cancer Center Sanford Burnham Prebys Medical Discovery Institute La Jolla CA 92037 USA
3. Department of Chemical and Systems Biology ChEM-H Stanford Cancer Institute School of Medicine Stanford University Stanford CA 94305 USA
4. Department of Biological Chemistry and Molecular Pharmacology Harvard Medical School Boston MA 02115 USA
Abstract
AbstractPhosphatidylinositol 5‐phosphate 4‐kinase, type II, gamma (PIP4K2C) remains a poorly understood lipid kinase with minimal enzymatic activity but potential scaffolding roles in immune modulation and autophagy‐dependent catabolism. Achieving potent and selective agents for PIP4K2C while sparing other lipid and non‐lipid kinases has been challenging. Here, we report the discovery of the highly potent PIP4K2C binder TMX‐4102, which shows exclusive binding selectivity for PIP4K2C. Furthermore, we elaborated the PIP4K2C binder into TMX‐4153, a bivalent degrader capable of rapidly and selectively degrading endogenous PIP4K2C. Collectively, our work demonstrates that PIP4K2C is a tractable and degradable target, and that TMX‐4102 and TMX‐4153 are useful leads to further interrogate the biological roles and therapeutic potential of PIP4K2C.
Funder
Foundation for the National Institutes of Health
Subject
General Chemistry,Catalysis
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献